Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

52 results about "Histone H3" patented technology

Histone H3 is one of the five main histone proteins involved in the structure of chromatin in eukaryotic cells. Featuring a main globular domain and a long N-terminal tail, H3 is involved with the structure of the nucleosomes of the 'beads on a string' structure. Histone proteins are highly post-translationally modified however Histone H3 is the most extensively modified of the five histones. The term "Histone H3" alone is purposely ambiguous in that it does not distinguish between sequence variants or modification state. Histone H3 is an important protein in the emerging field of epigenetics, where its sequence variants and variable modification states are thought to play a role in the dynamic and long term regulation of genes.

Method for changing cell fate

InactiveCN104250291AChange destinyFacilitate reprogrammingDepsipeptidesVector-based foreign material introductionHeterochromatinHistone H3
The invention discloses a method for changing cell fate, a construct, a method for changing expression quantity and positioning of cell heterochromatin protein HP 1a in cell, a method for changing a structure of cell chromatin, and a method for changing the cell histone H3 methylation and cells thereof. The method for changing the cell fate comprises protein selected from one of following amino acid sequences by the cell overexpression: a)an amino acid sequence shown by at least one of SEQ ID NO: 1-3; b)a part of an amino acid sequence shown by at least one of SEQ ID NO: 1-3; and c)an amino acid sequence having at least 80% of homogeneity with the amino acid sequences shown in the a) or b). The method can be used for using cell overexpression Gadd45 family protein for effectively open the cell chromatin, so that the cell fate can be conveniently and effectively changed, and especially reprogramming of somatic cell can be promoted.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Signal-enhanced test strip biosensor for detecting histone methylation

ActiveCN103389382AAvoid the disadvantages of complicated operation steps and long operation timeEnhanced detection signalBiological testingHistone methylationAntiendomysial antibodies
The invention relates to a signal-enhanced test strip biosensor for detecting histone methylation. The test strip biosensor comprises a bottom plate with viscidity, a nitrocellulose membrane, a colloidal gold pad, an absorbent paper, and a sample pad, wherein the nitrocellulose membrane is attached to the middle part of the bottom plate; a monoclonal antibody of anti-histone H3 and a goat-anti-rat IgG antibody are sprayed on the nitrocellulose membrane; a detection line and a quality control line are respectively formed; the colloidal gold pad is attached to the bottom plate at one side of the nitrocellulose membrane; gold nanoparticle solution doubly marked by c-DNA (deoxyribonucleic acid) and the monoclonal antibody of anti-histone H3 is sprayed on the colloidal gold pad; the absorbent paper is attached to the bottom plate at the other side of the nitrocellulose membrane; the sample pad is attached to the bottom plate; histone extract is firstly dropwise added to the sample pad in detection; then an enhanced probe formed by DNA and gold nanoparticles in a coupling manner is dropwise added. By adopting the test strip biosensor provided by the invention, the histone methylation condition can be simply and rapidly detected; a detection signal is further amplified by the enhanced probe.
Owner:GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI

Imipridones for gliomas

Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.
Owner:ONCOCEUTICS

Primer and probe for fluorescence quantitative PCR of phomopsis amydalina TaqMan

The invention relates to a primer and a probe for a fluorescence quantitative PCR of phomopsis amydalina TaqMan. The primer is characterized by comprising a primer pair formed by an upstream primer histone H3-F shown as the SEQ ID No:1 and a downstream primer histone H3-R shown as the SEQ ID No:1. The probe used for detecting phomopsis amydalina is a probe histone H3-P shown as the SEQ ID No:1. The end 5' of the probe histone H3-P marks a fluorescence reporter group FAM, and the end 3' of the probe histone H3-P marks a fluorescence quenching group TAMRA. A method for detecting phomopsis amydalina is characterized by comprising the steps that 1, the upstream primer histone H3-F, the downstream primer histone H3-R and the probe histone H3-P are synthesized, and the probe histone H3-P is marked; 2, genome DNA of a sample to be detected is extracted, and amplification is performed with the upstream primer histone H3-F and the downstream primer histone H3-R to obtain an amplification product; 3, a fluorescence quantitative PCR detection system is adopted for detecting the sample to be detected. The primer and the probe are suitable for fluorescence quantitative PCR detection of phomopsis amydalina TaqMan, and rapidity, sensitivity, simplicity and convenience are achieved.
Owner:WUXI ENTRY EXIT INSPECTION & QUARANTINE BUREAU PEOPLES REPUBLIC OF CHINA

Methods for predicting responsiveness of a cancer to an immunotherapeutic agent and methods of treating cancer

The invention generally relates to methods for predicting responsiveness of a cancer to an immunotherapeutic agent and methods of treating cancer. More specifically, the invention relates in part to the use of histone H3 lysine (27) trimethylation (H3K27me3), E-cadherin, and other biomarkers to treat cancer and determine the responsiveness of a cancer tumor to treatment with an immunotherapeutic agent.
Owner:BIOVENTURES LLC

CARM1 small-molecule inhibitor and application thereof

The invention discloses a CARM1 small-molecule inhibitor and application thereof. The small-molecule inhibitor can effectively inhibit the proliferation of prostate cancer cells. The provided CARM1 small-molecule inhibitor has the low toxicity to normal cells and has the significant inhibitory effect on CARM1-mediated histone H3R17me2a modification and expression of a target gene PSA in the downstream of the histone, the proliferation of tumor cells can be effectively inhibited, and thus the CARM1 small-molecule inhibitor is expected to be developed into a new antitumor drug; and the in vitroand vivo therapeutical effects on prostate cancer, non-small cell lung cancer, breast cancer, acute and chronic leukemia, liver cancer, stomach cancer, colorectal cancer, ovarian cancer, cervical cancer are achieved.
Owner:CHINA AUSTRALIA INST OF TRANSLATIONAL MEDICINE CO LTD NANJING CHINA

New histone methyltransferase 1 expression level reducing function of karounitriol

Karounitriol is an important active ingredient from Semen Trichosanthis which is a traditional Chinese medicinal material. The invention introduces a new function of the karounitriol. Through action experiment on primary cultured neuron of a rat, the expression level of an EZH1 gene can be reduced by adding the karounitriol. The EZH 1 is a key enzyme causing methylation of histone H3, methylation of histone is an important constituent part of epigenetics, and change of the histone shows that a nervous system has global stress reaction on the karounitriol, and the karounitriol has remarkable regulating effect on activity of the nervous system.
Owner:南京思恩倍医药科技有限公司

Application of CIT-H3 protein detection reagent in preparation of liver cancer prognosis and/or recurrence prediction reagent

The invention discloses an application of a CIT-H3 protein detection reagent in preparation of a liver cancer prognosis and / or recurrence prediction reagent, and provides an immunohistochemical detection kit for evaluating the prognosis and recurrence risk of a liver cancer patient. According to the principle of immunohistochemistry, the kit detects a marker CIT-H3 (citrullinated histone H3) of a neutrophile granulocyte extracellular trap net, has the characteristics of being objective, accurate, simple, convenient, intuitive, easy to operate and the like, and can be operated by common technicians in a hospital pathology room without the help of complex instruments; the prognosis and recurrence risk of the liver cancer patient can be effectively evaluated, so that a doctor is better helped to monitor the condition of the patient, proper treatment means are adjusted in time, the treatment effect is improved, and the survival time of the patient is prolonged.
Owner:SUN YAT SEN UNIV

Generation of haploid plants

The present invention relates to non-transgenic and transgenic plants, preferably crop plants, having biological activity of a haploid inducer and comprising a polynucleotide which comprises a nucleotide sequence encoding a centromer histone H3 (CENH3) protein, wherein the polynucleotide comprises at least one mutation causing an alteration of the amino acid sequence of the CENH3 protein, and to a part of the part. Further, the invention provides methods of generating the inducer plants, methods of generating haploid and double haploid plants using the inducer plants as well as methods of facilitating cytoplasm exchange.
Owner:KWS SAAT SE & CO KGAA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products